Susanna S Park1, Gerhard Bauer2, Mehrdad Abedi3, Suzanne Pontow2, Athanasios Panorgias1, Ravi Jonnal1, Robert J Zawadzki1, John S Werner1, Jan Nolta2. 1. Department of Ophthalmology and Vision Science, University of California-Davis Eye Center, Sacramento, California, United States. 2. Institute for Regenerative Cures, University of California-Davis School of Medicine, Sacramento, California, United States. 3. Division of Hematology and Oncology, University of California-Davis Cancer Center, Sacramento, California, United States.
Abstract
PURPOSE: Because human bone marrow (BM) CD34+ stem cells home into damaged tissue and may play an important role in tissue repair, this pilot clinical trial explored the safety and feasibility of intravitreal autologous CD34+ BM cells as potential therapy for ischemic or degenerative retinal conditions. METHODS: This prospective study enrolled six subjects (six eyes) with irreversible vision loss from retinal vascular occlusion, hereditary or nonexudative age-related macular degeneration, or retinitis pigmentosa. CD34+ cells were isolated under Good Manufacturing Practice conditions from the mononuclear cellular fraction of the BM aspirate using a CliniMACs magnetic cell sorter. After intravitreal CD34+ cell injection, serial ophthalmic examinations, microperimetry/perimetry, fluorescein angiography, electroretinography (ERG), optical coherence tomography (OCT), and adaptive optics OCT were performed during the 6-month follow-up. RESULTS: A mean of 3.4 million (range, 1-7 million) CD34+ cells were isolated and injected per eye. The therapy was well tolerated with no intraocular inflammation or hyperproliferation. Best-corrected visual acuity and full-field ERG showed no worsening after 6 months. Clinical examination also showed no worsening during follow-up except among age-related macular degeneration subjects in whom mild progression of geographic atrophy was noted in both the study eye and contralateral eye at 6-month follow-up, concurrent with some possible decline on multifocal ERG and microperimetry. Cellular in vivo imaging using adaptive optics OCT showed changes suggestive of new cellular incorporation into the macula of the hereditary macular degeneration study eye. CONCLUSIONS:Intravitreal autologous BM CD34+ cell therapy appears feasible and well tolerated in eyes with ischemic or degenerative retinal conditions and merits further exploration. (ClinicalTrials.gov number, NCT01736059.). Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
RCT Entities:
PURPOSE: Because human bone marrow (BM) CD34+ stem cells home into damaged tissue and may play an important role in tissue repair, this pilot clinical trial explored the safety and feasibility of intravitreal autologous CD34+ BM cells as potential therapy for ischemic or degenerative retinal conditions. METHODS: This prospective study enrolled six subjects (six eyes) with irreversible vision loss from retinal vascular occlusion, hereditary or nonexudative age-related macular degeneration, or retinitis pigmentosa. CD34+ cells were isolated under Good Manufacturing Practice conditions from the mononuclear cellular fraction of the BM aspirate using a CliniMACs magnetic cell sorter. After intravitreal CD34+ cell injection, serial ophthalmic examinations, microperimetry/perimetry, fluorescein angiography, electroretinography (ERG), optical coherence tomography (OCT), and adaptive optics OCT were performed during the 6-month follow-up. RESULTS: A mean of 3.4 million (range, 1-7 million) CD34+ cells were isolated and injected per eye. The therapy was well tolerated with no intraocular inflammation or hyperproliferation. Best-corrected visual acuity and full-field ERG showed no worsening after 6 months. Clinical examination also showed no worsening during follow-up except among age-related macular degeneration subjects in whom mild progression of geographic atrophy was noted in both the study eye and contralateral eye at 6-month follow-up, concurrent with some possible decline on multifocal ERG and microperimetry. Cellular in vivo imaging using adaptive optics OCT showed changes suggestive of new cellular incorporation into the macula of the hereditary macular degeneration study eye. CONCLUSIONS: Intravitreal autologous BM CD34+ cell therapy appears feasible and well tolerated in eyes with ischemic or degenerative retinal conditions and merits further exploration. (ClinicalTrials.gov number, NCT01736059.). Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Rachel L McIntosh; Sophie L Rogers; Lyndell Lim; Ning Cheung; Jie Jin Wang; Paul Mitchell; Jonathan W Kowalski; Hiep P Nguyen; Tien Yin Wong Journal: Ophthalmology Date: 2010-06 Impact factor: 12.079
Authors: Susanna S Park; Sergio Caballero; Gerhard Bauer; Bradley Shibata; Alan Roth; Paul G Fitzgerald; Krisztina I Forward; Ping Zhou; Jeannine McGee; David G Telander; Maria B Grant; Jan A Nolta Journal: Invest Ophthalmol Vis Sci Date: 2012-02-23 Impact factor: 4.799
Authors: Carl M Sheridan; Stephanie Pate; Paul Hiscott; David Wong; David M Pattwell; David Kent Journal: Graefes Arch Clin Exp Ophthalmol Date: 2009-07-10 Impact factor: 3.117
Authors: Atsushi Otani; Michael Ian Dorrell; Karen Kinder; Stacey K Moreno; Steven Nusinowitz; Eyal Banin; John Heckenlively; Martin Friedlander Journal: J Clin Invest Date: 2004-09 Impact factor: 14.808
Authors: Ajay E Kuriyan; Thomas A Albini; Justin H Townsend; Marianeli Rodriguez; Hemang K Pandya; Robert E Leonard; M Brandon Parrott; Philip J Rosenfeld; Harry W Flynn; Jeffrey L Goldberg Journal: N Engl J Med Date: 2017-03-16 Impact factor: 91.245
Authors: Susanna S Park; Elad Moisseiev; Gerhard Bauer; Johnathon D Anderson; Maria B Grant; Azhar Zam; Robert J Zawadzki; John S Werner; Jan A Nolta Journal: Prog Retin Eye Res Date: 2016-10-23 Impact factor: 21.198
Authors: Mandeep S Singh; Susanna S Park; Thomas A Albini; M Valeria Canto-Soler; Henry Klassen; Robert E MacLaren; Masayo Takahashi; Aaron Nagiel; Steven D Schwartz; Kapil Bharti Journal: Prog Retin Eye Res Date: 2019-09-05 Impact factor: 21.198
Authors: Jeffrey H Stern; Yangzi Tian; James Funderburgh; Graziella Pellegrini; Kang Zhang; Jeffrey L Goldberg; Robin R Ali; Michael Young; Yubing Xie; Sally Temple Journal: Cell Stem Cell Date: 2018-06-01 Impact factor: 24.633